dynamic changes need to be considered when using foci as a marker to monitor the effects of therapeutic drugs.
Introduction
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder and is characterized by progressive weakness and muscle wasting, myotonia, cardiac arrhythmias, central nervous system (CNS) involvement, cataracts and endocrinopathies (Bassez et al. 2004; Groh et al. 2008; Harper 2001a, b) . DM1 is caused by an unstable CTG repeat expansion (>50 repeats) in the 3′-untranslated region of the DMPK gene (Fu et al. 1992) . As a result of the expansion, RNA transcripts containing CUG expanded (CUG exp ) repeats are retained in the nucleus as a hairpin structure (Jasinska et al. 2003; Kino et al. 2004; Tian et al. 2000) that accumulates as nuclear RNA foci (Jiang et al. 2004; Lin et al. 2006; Mahadevan et al. 2006; Mankodi et al. 2000; Orengo et al. 2008; Seznec et al. 2001; Taneja et al. 1995; Wang et al. 2007 ). In these foci, CUG exp RNA sequesters splicing factors, including MBNL 1 and 2, which results in splicing dysregulation of many target gene transcripts. Dysregulated splicing has been found to be responsible for specific phenotypes of DM1, including myotonia and insulin insufficiency (Ashizawa and Sarkar 2011; de Leon and Cisneros 2008; Lee and Cooper 2009; Llamusi and Artero 2008; Ranum and Cooper 2006; Schara and Schoser 2006) . Thus, nuclear RNA foci containing expanded CUG repeats are the molecular hallmark of the RNA gain-offunction pathomechanism of DM1. Nuclear RNA foci have also been used as a marker for therapeutic approaches
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Materials and methods

Reagent
Mitomycin C (M4287) and an anti-alpha-tubulin monoclonal antibody (T9025, clone DM1A) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The NeuroCult™ NS-A proliferation kit (#05751) is from STEMCELL Technologies (Vancouver, Canada).
Cells and culture DM-03 NSCs were generated from the neural induction of human DM-03 iPS cells (Xia et al. 2013 ) and expanded in the NeuroCult™ NS-A proliferation medium. Normal control NSCs were derived from normal iPS cells which were generated from a 51-year-old male healthy donor. DM-03 FBs are from the primary culture of the same subject that was used for generation of iPS cells. FBs were cultured in DMEM with 20 % FBS in 5 % CO 2 .
Mitomycin C treatment
NSCs were cultured under proliferating growth conditions in a 24-well plate in triplicate to densities of ~80, and ~30 % confluence. For the first three wells (~80 % confluence), cells were treated with mitomycin C (10 μg/ mL) for 3 h and then changed to normal growth medium and cultured for 8 days. For the other three wells (~30 % confluence), cells were not treated with mitomycin C and cultured for 8 days when they became 80 % confluence. 3 × 10 3 cells were then transferred to each well of ibidiTreat u-Slides (ibidi GmbH, Am Klopferspitz 19, 85152 Martinsried, Germany) for fluorescent in situ hybridization (FISH) and immunofluorescence (IF) staining.
FISH, foci quantification and immunofluorescence staining of alpha-tubulin FISH was performed as previously described (Xia et al. 2013) . Cells were plated in ibidiTreat μ-slides, fixed in 10 % buffered formalin phosphate and then dehydrated in pre-chilled 70 % ethanol. The cells were then hybridized with Cy3-labeled (CAG) 10 DNA probes (500 pg/μL) after pretreatment. After hybridization, cells were washed three times in pre-warmed 40 % formamide/2× SCC buffer for 30 min at 37 °C and once in PBS (pH 7.4) followed by IF staining as described (Xia et al. 2013) . Cells were incubated overnight at 4 °C with antibodies against alphatubulin (1:1000). On the following day, slides were washed and incubated with the secondary antibody conjugated with Alexa Fluor 488 (Invitrogen) (1:500) for 30 min at room temperature. Finally, the slides were washed with PBS and mounted with Vectashield mounting medium containing DAPI. Photomicrographs were taken using Olympus IX81-DSU Spinning Disk confocal microscope. Confocal images were captured in a z-stack interval of 0.5-μm increments using a 60× objective to quantify the foci within the cellular volume. Foci number and area in each cell were analyzed by ImageJ. Mitotic phases were identified by mitotic spindle and chromosome morphologies. Even when cells were growing at exponential condition, we still saw some cells that had very large nuclei, which could be terminally differentiated cells or entering senescence and we classified them as G0 cells. Or we saw fragmented nuclei, which we classified as dying cells.
Statistical analysis
Foci number or area during different phases of the cell cycle and in nonproliferating cells was compared by independent-samples t test. P values less than 0.05 are considered statistically significant.
Results
DM1 ribonucleic foci are dynamic during cell cycles
In proliferating DM1 iPS-cell-derived NSCs, the number and size of RNA foci varied, consistent with those reported in the literature (Mankodi et al. 2003) . Some cells contained more foci than others, and cytoplasmic foci were occasionally seen (Fig. 1) . This variability could be attributed to differences in cell cycle stage with some cells committed to terminal neural differentiation, while other cells were in different stages of mitosis. To test this hypothesis, cells were grouped according to cell cycle stage and examined for the number of nuclear RNA foci. As shown in Fig. 2 , we found that RNA foci underwent dynamic changes during the cell cycle with foci most abundant just prior to entering mitosis (early prophase). During mitosis and with the breakdown of the nuclear envelope, the majority of RNA foci disappeared. Following cytokinesis, the remaining foci were randomly distributed to daughter cells and when the nuclear membrane reformed, foci were either enveloped by nuclear membrane or stayed in cytoplasm. Nuclear RNA foci further accumulated in interphase, while cytoplasmic RNA foci eventually disappeared prior to entering prophase. In the G0 cells or the aged cells (identified by morphology), nuclear RNA foci accumulated and grew larger and cytoplasmic foci were not detectable in these cells. Significantly more foci were observed in prophase and G0 in contrast to metaphase-telophase (Fig. 3) . Occasionally, dying cells were seen with abundant nuclear RNA foci. No foci were seen in normal iPS-cell-derived NSCs (Fig. 4) . These findings suggest that mitosis is a mechanism to decrease foci load in the nuclei of proliferating cells.
Nuclear RNA foci progressively increase in number and become larger in size when cells get out of cell cycle and start aging We next examined how foci changed when DM1 NSCs stopped dividing and started aging. After we stopped cell division with treatment of mitomycin C, we found that nuclear RNA foci started accumulating in number, size and fluorescence intensity as time passed (Fig. 5) . Foci had significantly increased on day 8 after treatment with mitomycin C (P < 0.01) (Fig. 6) . The biggest foci could reach to 2 μm in diameter comparable to the largest foci found in autopsy brain neurons (Jiang et al. 2004 ). We never observed cytoplasmic foci on day 8 after mitomycin C treatment.
Discussion
The current study investigated nuclear RNA foci changes in NSCs differentiated from human DM1 iPS cells. Previous studies of nuclear RNA foci in human DM1 CNS were mainly on postmortem autopsy brains (Jiang et al. 2004) . Using the DM1 iPS-cell-derived NSCs enabled us to demonstrate the dynamic changes of CUG repeat foci in cultured human neural lineage cells. In NSCs, foci start accumulating in interphase and reach the most abundant level before prophase. When cells enter mitosis, most foci dissipate, while some of the remaining foci randomly move to cytoplasm after mitosis. The cytoplasmic foci will eventually dissipate. A previous study has shown that cytoplasmic CUG foci are not sufficient to elicit key DM1 features (Dansithong et al. 2008) . It is plausible that a cytoplasm environment is not compatible for expanded CUG RNA repeats to form stable foci. The remaining nuclear RNA foci appear to grow in size and accompany formation of additional new foci as the cells enter another cycle. The same findings were also found in DM1 fibroblast in this study (data not shown). These observations raise a concern in using proliferating cells, such as myoblast (Dansithong et al. 2005; Langlois et al. 2003; Mulders et al. 2009 ), fibroblast ) and NSCs (here) and engineered cells (HeLa cells and COSM6 cells) (Lee et al. 2012; Parkesh et al. 2012; Warf et al. 2009 ), as cellular models for DM1 study, especially when using foci as a marker for drug screening (Ketley et al. 2014) . The natural dynamic changes need to be considered in the evaluation. Ideally, cells should be synchronized to G0 stage.
The dynamic changes of foci were also found in DM2 fibroblast cells (Giagnacovo et al. 2012 ). It will be interesting to see whether similar phenomenon exists in other microsatellite expansion disorders which have also been shown to have a RNA gain of function. These include fragile X-associated tremor ataxia syndrome (FXTAS, CGG repeat), Huntington's disease-like 2 (HDL2, CUG repeat), spinocerebellar ataxias type 8 (SCA8, CUG/CAG repeat), type 31 (SCA 31, UGGAA repeat) and type 10 (SCA 10, AUUCU repeat) and familial ALS with GGGGCC repeat expansion in C9ORF72 gene (Daughters et al. 2009; Rudnicki et al. 2007; Sato et al. 2009; Sellier et al. 2010; White et al. 2010 ) (DeJesus-Hernandez et al. 2011) . The lower load of nuclear RNA foci in NSCs suggests that these cells are protected by either low expression of DMPK or high a proliferating rate, which will not allow foci to grow.
We found that nuclear RNA foci increase in number and size as cells grow. Even though the sequestration of MBNL proteins into the CUG foci is considered to play the major role in the DM1 disease mechanism, the increasing of foci size may imply further gain of function. The larger nuclear RNA foci may have different quaternary structures in nonproliferating cells. ASO or small molecules may not have the same effect on reducing the foci burden compared with newly formed nuclear RNA foci in highly proliferating cells. The current study offers a model to study the effect of therapeutic drugs on foci in different cell cycle stages.
We have adapted the iPS-cell-derived DM1 NSCs to be cultured in routine culture medium (20 % FBS in DMEM). These cells are easily maintained and have been passed to passage 23 and are still in healthy proliferating condition. Furthermore, iPS cell can provide unlimited cell resources. They are relatively homogeneous. We found that nuclear RNA foci in these cells vary in a wide range in abundance (number, size and immunofluorescence density). With the advancement of imaging techniques and quantification software as newly developed Volocity 3D Image Analysis Software (PerkinElmer), foci can be more precisely and reliably quantified. We think that these cells can be used as an ideal cellular model for therapeutic drug development by monitoring nuclear RNA foci as molecular marker.
In summary, the current study suggests that nuclear RNA foci of DM1 neural stem cells undergo dynamic changes during cell cycle. Mitosis is a mechanism to decrease foci load. When cells get out of cell cycle, foci abundance progressively increases. The dynamic changes need to be considered when using foci as a marker to follow the effects of therapeutic drugs. 
